The organizations that are seeing the most success with AI governance are generally not creating large, centralized "AI committees" that review everything. Instead, they establish risk-based governance that combines clear executive accountability with distributed operational ownership. The governance model looks less like a compliance exercise and more like a clinical quality and patient safety program.
A practical framework typically has five layers.
| Layer | Purpose | Typical owner |
|---|
| Executive governance | Strategy, risk appetite, investment | CEO, COO, Chief Medical Officer, Board committee |
| AI oversight committee | Cross-functional review and prioritization | Clinical, IT, legal, compliance, data science |
| Domain ownership | Accountability for each AI application | Clinical department or operational leader |
| Technical governance | Validation, monitoring, security | Data science, informatics, IT |
| Frontline feedback | User reporting and continuous improvement | Clinicians and operational teams |
1. Executive sponsorship matters more than the committee structure
Successful health systems usually assign one executive who is ultimately accountable for enterprise AI, often:
- Chief Medical Information Officer (CMIO)
- Chief Digital Officer
- Chief AI Officer (in larger systems)
- Chief Clinical Officer with informatics leadership
The board typically doesn't approve every AI model. Instead, it oversees:
- enterprise AI strategy
- material patient safety risks
- regulatory compliance
- cybersecurity
- ethical principles
AI is treated similarly to medication safety or clinical quality rather than as a standalone technology initiative.
2. Create a multidisciplinary AI governance committee
The most effective committees are intentionally small (roughly 10–15 members) and include:
Clinical
- physicians
- nursing leadership
- pharmacy
- quality and safety
Operational
- IT
- clinical informatics
- data science
- cybersecurity
Risk
- legal
- compliance
- privacy
- ethics
Business
- finance
- operations
- procurement
Some organizations also include a patient representative for high-impact clinical AI.
The committee focuses on decisions that require multidisciplinary judgment rather than reviewing every technical detail.
3. Use a risk-tiering process
This is probably the biggest differentiator between governance that works and governance that becomes a bottleneck.
Rather than treating all AI equally:
Low risk
Examples:
- meeting summarization
- policy search
- drafting emails
- administrative copilots
Governance:
- standard security review
- privacy review
- departmental approval
Deployment may take days.
Medium risk
Examples:
- coding assistance
- documentation support
- scheduling optimization
- operational forecasting
Governance:
- validation
- workflow testing
- limited pilot
- monitoring plan
Deployment may take weeks.
High risk
Examples:
- diagnostic support
- sepsis prediction
- treatment recommendations
- imaging interpretation
- triage algorithms
Governance includes:
- clinical evidence review
- bias assessment
- prospective validation
- human oversight requirements
- safety monitoring
- post-deployment surveillance
Deployment may take months.
This risk-based approach prevents governance from becoming a bottleneck for low-risk tools while maintaining rigorous oversight where patient safety is directly affected.
4. Standardize the AI intake process
Leading organizations require every AI project to answer a common set of questions before implementation, such as:
- What problem are we solving?
- Who owns the model?
- Who is accountable after deployment?
- What data are used?
- Does protected health information leave the organization?
- What evidence supports effectiveness?
- What biases have been evaluated?
- How will performance be monitored?
- What happens if the model fails?
- How can it be turned off?
This functions as an AI equivalent of introducing a new clinical service line.
5. Separate approval from monitoring
One lesson from early deployments is that governance doesn't end at go-live.
Operational monitoring should include:
Technical
- model drift
- uptime
- latency
- hallucination rates (for generative AI)
- API failures
Clinical
- outcome measures
- override rates
- clinician trust
- adverse events
Operational
- productivity
- workflow disruption
- adoption
- cost
Many organizations establish dashboards with review intervals (e.g., monthly or quarterly) based on the application's risk level.
6. Define ownership clearly
Every AI system should have a designated owner responsible for:
- approving updates
- reviewing performance
- responding to incidents
- coordinating vendor interactions
- determining retirement or replacement
Ownership is typically assigned to a clinical or operational leader, not solely to IT.
7. Integrate AI governance with existing governance
The most mature organizations avoid creating isolated AI structures. Instead, AI governance connects with existing committees for:
- clinical quality
- patient safety
- cybersecurity
- privacy
- technology architecture
- procurement
- research oversight
This leverages established expertise and reporting pathways rather than duplicating them.
8. Establish clear policies for generative AI
Health systems increasingly adopt enterprise policies that address:
- approved vs. prohibited AI tools
- acceptable use
- handling of protected health information
- human review requirements
- documentation standards
- attribution of AI-generated content
- copyright and intellectual property
- vendor security requirements
These policies help prevent inconsistent use across departments.
9. Measure governance effectiveness
Effective governance is assessed not only by compliance but also by operational performance. Useful metrics include:
- Time from proposal to decision
- Percentage of AI systems with identified owners
- Validation completion rate
- AI-related safety events
- Clinician adoption and satisfaction
- Number of systems under continuous monitoring
- Model retirements or retraining events
- Return on investment for approved use cases
Common pitfalls
Several recurring issues can undermine AI governance:
- Reviewing every AI use case with the same rigor, which slows innovation without improving safety.
- Treating AI as solely an IT responsibility, rather than a shared clinical, operational, and organizational concern.
- Focusing only on pre-deployment approval, while neglecting ongoing monitoring and lifecycle management.
- Leaving accountability unclear, especially when multiple departments are involved.
- Failing to define acceptable uses of generative AI, leading to inconsistent practices and increased privacy or security risks.
What mature health systems are converging toward
Across large integrated delivery networks and academic medical centers, a common operating model is emerging:
- An executive AI steering committee sets strategy and organizational priorities.
- A multidisciplinary AI governance committee reviews medium- and high-risk applications.
- Low-risk tools follow streamlined approval pathways.
- Every AI system has a named clinical or operational owner.
- High-risk clinical AI undergoes validation before deployment and continuous post-deployment monitoring.
- AI governance is embedded within existing quality, safety, privacy, cybersecurity, and procurement processes rather than operating as a standalone function.
This approach balances innovation with patient safety and organizational accountability, allowing health systems to scale AI adoption without creating unnecessary administrative burden.
